

**From:** [REDACTED]  
**To:** [REDACTED]  
**Subject:** Minutes of meeting with Cefic on chemicals strategy - 15 June 2020  
**Date:** vendredi 24 juillet 2020 14:47:31  
**Attachments:** [image001.png](#)

---

## **Minutes of meeting with Cefic on chemicals strategy for sustainability.**

Date: 15 June 2020

Participants:

- [REDACTED] (Cefic)
- [REDACTED]  
[REDACTED] (DG GROW D1/D2)

Cefic drafted several papers on topics related to the chemicals strategy which have been or will be shared with the Commission services. On the one substance, one assessment approach,

- they indicated their concern with different official assessments potentially leading to different conclusions, in particular for hazard identification.
- They advocated for requesting test according to the same testing protocols under different pieces of legislation, without the aggregation of all possible information requirements; e.g. when required, a one-generation test should be required according to the same protocol in different pieces of legislation.
- Risk assessment should be done sectorially, given the specificity of each sector.
- In terms of expertise of scientific bodies and agencies, Cefic indicated the need to optimize the available expertise and indicated that ECHA's Risk Assessment Committee could benefit from certain additional expertise.
- In addition, Cefic expressed supporting more formalisation of the current risk management option analysis (RMOA), as such formalisation would also improve regulatory predictability.

On the inclusion of identification criteria for endocrine disruptors in EU chemicals legislation,

- Cefic stated not being in favour of covering this under the CLP Regulation, as this would constitute a major departure from how the introduction of new hazard classes has been done in the past, namely via GHS first. Going via CLP first and only afterwards to GHS would be a problematic change of sequence as agreement at GHS level may be difficult to obtain, leaving the EU isolated.
- Instead, Cefic suggested dealing with EDs via REACH, as is being done today via SVHC identification, or via an Annex approach like for PBTs (Annex XIII).

DG GROW D1/D2 thanked Cefic for the expression of their views. With regard to one substance, one assessment it expressed also supporting more formalisation of RMOA. As concerns EDs, it stated that any potential coverage under REACH would also depend on

the question whether or not to re-open REACH which is still under discussion. DG GROW D1/D2 closed the meeting by briefly recapitulating the next steps for the adoption of the chemicals strategy.



**European Commission**

DG for Internal Market, Industry, Entrepreneurship and SMEs  
Chemicals Industry Unit (D2)  
B - 1049 Brussels



Follow us on

Facebook: [EU Growth](#)

Twitter: [@EU\\_Growth](#)

Our Websites: [ec.europa.eu/growth](http://ec.europa.eu/growth)  
[ec.europa.eu/bienkowska](http://ec.europa.eu/bienkowska)

*Please note that this e-mail contains the personal opinion of the author and does not necessarily reflect the official opinion or constitute a formal commitment of the European Commission.*